 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz= Reporter Paul Lee] Celltrion has signed a ZYMFENTRA listing contract with the largest PBM in the United States.
Celltrion announced on the 29th that it has signed an ZYMFENTRA listing contract with Express Scripts (ESI), which has 100 million subscribers throughout the United States. Through the contract, which went into effect on the 4th of this month, ZYMFENTRA was listed as a preferred drug in the ESI prescription book with 21.9 million coverage.
ZYMFENTRA is the world's only Infliximab subcutaneous injection (SC) formulation approved by the US Food and Drug Administration (FDA) and is currently sold in the United States.
Celltrion plans to continue to cooperate with PBM and drug purchasing agencies (GPO) as well as national and regional health plans to further convey the value of the company's products approved by FDA, including ZYMFENTRA, a treatment for autoimmune diseases.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
